285 related articles for article (PubMed ID: 25192188)
1. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells.
Koehler BC; Scherr AL; Lorenz S; Elssner C; Kautz N; Welte S; Jaeger D; Urbanik T; Schulze-Bergkamen H
PLoS One; 2014; 9(9):e106571. PubMed ID: 25192188
[TBL] [Abstract][Full Text] [Related]
2. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
3. Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.
Or CR; Chang Y; Lin WC; Lee WC; Su HL; Cheung MW; Huang CP; Ho C; Chang CC
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28035994
[TBL] [Abstract][Full Text] [Related]
4. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
[TBL] [Abstract][Full Text] [Related]
5. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
Konopleva M; Watt J; Contractor R; Tsao T; Harris D; Estrov Z; Bornmann W; Kantarjian H; Viallet J; Samudio I; Andreeff M
Cancer Res; 2008 May; 68(9):3413-20. PubMed ID: 18451169
[TBL] [Abstract][Full Text] [Related]
7. Comparison of in vitro antileukemic activity of obatoclax and ABT-737.
Opydo-Chanek M; Mazur L
Tumour Biol; 2016 Aug; 37(8):10839-49. PubMed ID: 26880588
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Anti-apoptotic Bcl-2 Family Proteins Exhibit Potent and Broad-Spectrum Anti-mammarenavirus Activity via Cell Cycle Arrest at G0/G1 Phase.
Kim YJ; Witwit H; Cubitt B; de la Torre JC
J Virol; 2021 Nov; 95(24):e0139921. PubMed ID: 34586865
[TBL] [Abstract][Full Text] [Related]
9. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis.
Wroblewski D; Jiang CC; Croft A; Farrelly ML; Zhang XD; Hersey P
PLoS One; 2013; 8(12):e84073. PubMed ID: 24367627
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
11. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
[TBL] [Abstract][Full Text] [Related]
12. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MCL-1 by obatoclax sensitizes Sp2/0-Ag14 hybridoma cells to glutamine deprivation-induced apoptosis.
Harnett CC; Abusneina A; Clément J; Gauthier ER
Cell Biochem Funct; 2015 Jul; 33(5):334-40. PubMed ID: 26178811
[TBL] [Abstract][Full Text] [Related]
14. Obatoclax, a Pan-BCL-2 Inhibitor, Downregulates Survivin to Induce Apoptosis in Human Colorectal Carcinoma Cells Via Suppressing WNT/β-catenin Signaling.
Or CR; Huang CW; Chang CC; Lai YC; Chen YJ; Chang CC
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150830
[TBL] [Abstract][Full Text] [Related]
15. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
Steele TM; Talbott GC; Sam A; Tepper CG; Ghosh PM; Vinall RL
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875757
[TBL] [Abstract][Full Text] [Related]
16. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
[TBL] [Abstract][Full Text] [Related]
17. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
Okumura K; Huang S; Sinicrope FA
Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
[TBL] [Abstract][Full Text] [Related]
18. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
19. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
20. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]